Literature DB >> 14768954

Magnitude of alloresponses to MHC class I/II expressing human cardiac myocytes is limited by their intrinsic ability to process and present antigenic peptides.

J Bruce Sundstrom1, Kimberley C Jollow, Veronique Braud, Francois Villinger, Andrew J McMichael, E Clinton Lawrencec, Edwin W Ades, Aftab A Ansari.   

Abstract

In this investigation we have explored the relationship between the weak allogenicity of cardiac myocytes and their capacity to present allo-antigens by examining the ability of a human cardiac myocyte cell line (W-1) to process and present nominal antigens. W-1 cells (HLA-A*0201 and HLA-DR beta1*0301) pulsed with the influenza A matrix 1 (58-66) peptide (M1) were able to serve as targets for the HLA-A*0201 restricted CTL line PG, specific for M1-peptide. However, PG-CTLs were unable to lyse W-1 target cells infected with a recombinant vaccinia virus expressing the M1 protein (M1-VAC). Pretreatment of these M1-VAC targets with IFN-gamma partially restored their ability to process and present the M1 peptide. However, parallel studies demonstrated that IFN-gamma pretreated W-1's could not process tetanus toxin (TT) or present the TT(830-843) peptide to HLA-DR3 restricted TT-primed T cells. Semi-quantitative RT-PCR measurements revealed significantly lower constitutive levels of expression for MHC class I, TAP-1/2, and LMP-2/7 genes in W-1s that could be elevated by pretreatment with IFN-gamma to values equal to or greater than those expressed in EBV-PBLs. However, mRNA levels for the genes encoding MHC class II, Ii, CIITA, and DMA/B were markedly lower in both untreated and IFN-gamma pretreated W-1s relative to EBV-PBLs. Furthermore, pulse-chase analysis of the corresponding genes revealed significantly lower protein levels and longer half-life expression in W-1s relative to EBV-PBLs. These results suggest that weak allogenicity of cardiac myocytes may be governed by their limited expression of MHC genes and gene products critical for antigen processing and presentation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14768954      PMCID: PMC2485424          DOI: 10.1080/10446670310001642410

Source DB:  PubMed          Journal:  Clin Dev Immunol        ISSN: 1740-2522


  2 in total

1.  Absence of donor-specific anti-HLA antibodies after ABO-incompatible heart transplantation in infancy: altered immunity or age?

Authors:  S Urschel; P M Campbell; S R Meyer; I M Larsen; J Nuebel; J Birnbaum; H Netz; K Tinckam; T Kauke; K Derkatz; J Y Coe; J L Platt; L J West
Journal:  Am J Transplant       Date:  2009-11-24       Impact factor: 8.086

2.  Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Authors:  Rod Balhorn; Monique Cosman Balhorn
Journal:  Oncotarget       Date:  2020-09-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.